Targeting The Defective Airway Macrophage Function In Chronic Obstructive Pulmonary Disease (COPD): A New Therapeutic Approach
Funder
National Health and Medical Research Council
Funding Amount
$710,928.00
Summary
COPD/emphysema is smoking-related, incurable and a leading cause of death. New treatments are urgently needed. We have reported that airway phagocyte dysfunction and inflammation in COPD or smoke-exposed mice can be improved by novel treatments including lectins and macrolide antibiotics. We now show that these effects can be greatly improved by low-dose aspirin. We will further investigate these therapies and also novel antibiotics that have been modified to lose their anti-bacterial activity
The Role Of Dendritic Cells In Graft-versus-host Disease After Allogeneic Stem Cell Transplantation.
Funder
National Health and Medical Research Council
Funding Amount
$317,633.00
Summary
Allogeneic bone marrow transplantation (BMT) remains the most effect curative treatment for patients with a number of malignant conditions, especially leukemia. Graft-versus-Host Disease (GVHD) ocurrs when the newly transplanted bone marrow (which includes the immune system) recognises the transplant recipient as foreign and mounts an immune attack against patient tissues. GVHD is the major complication of BMT and is responsible for the death of up to half of the patients who receive this proced ....Allogeneic bone marrow transplantation (BMT) remains the most effect curative treatment for patients with a number of malignant conditions, especially leukemia. Graft-versus-Host Disease (GVHD) ocurrs when the newly transplanted bone marrow (which includes the immune system) recognises the transplant recipient as foreign and mounts an immune attack against patient tissues. GVHD is the major complication of BMT and is responsible for the death of up to half of the patients who receive this procedure. Research to date by Dr Hill and colleages has provided substantial detail on how and why this process occurs. This information has led to a number of advances in the field which are already improving patient survival after BMT. This includes a new type of bone marrow transplantation that uses a naturally ocurring growth factor (called a cytokine) to allow the collection of immature bone marrow cells from the blood of transplant donors. The transplantation of these cells rather than bone marrow appears to reduce the chance of dying during BMT and also improves the cure rates from the underlying leukemia. In addition, Dr Hill has developed a novel method for preventing GVHD using different types of naturally ocurring growth factors called cytokine shields that help protect patient tissue from attack by the immune system. It has recently become clear that the immune system is directed by a subtype of white cells called dendritic cells and Professor Hart at the Mater Medical Research Institute has been a pioneer in this field. As initiators of the immune system it is likely that dendritic cells play a pivotal role in GVHD and Dr Hill and Prof Hart at the Mater Medical Research Institute will study DC within the context of Dr Hills newly developed therapies with the aim of further understanding the processes of GVHD. This work will allow manipulation of these cells during BMT in order to improve patient survival.Read moreRead less
Five Year Outcomes Of Care For Prostate Cancer In New South Wales
Funder
National Health and Medical Research Council
Funding Amount
$388,773.00
Summary
Prostate cancer is the most common cancer in Australian males after non-melanocytic skin cancer. Each year more than 10,000 men are diagnosed with prostate cancer, and over 2,500 die from it. While the issue of early detection of prostate cancer through the use of Prostate Specific Antigen test continues to raise debate, the longer term quality of life outcomes after treatment for this disease remain of great interest to patients, clinicians and health planners. The Prostate Cancer Outcomes Stud ....Prostate cancer is the most common cancer in Australian males after non-melanocytic skin cancer. Each year more than 10,000 men are diagnosed with prostate cancer, and over 2,500 die from it. While the issue of early detection of prostate cancer through the use of Prostate Specific Antigen test continues to raise debate, the longer term quality of life outcomes after treatment for this disease remain of great interest to patients, clinicians and health planners. The Prostate Cancer Outcomes Study is an already established research project that was established in 2000 with the aim of documenting the quality of life outcomes of 2000 men with prostate cancer to five years after diagnosis. The Department of Veterans Affairs funded the study between 2000 and 2005, to establish the cohort, collect patterns of care information from clinicians and quality of life information from participants to 3 years post diagnosis. We are now seeking funds to complete the quality of life follow up for each surviving participant at five years after diagnosis. We also will assess rate of recurrence of prostate cancer to five years and seek support to be able to undertake linkage with death certificate information to determine the vital status of each study subject and begin analysis of five-year survival rates. Five-year quality of life information will be the main endpoint for this part of the study. Initial analysis of the three-year data showed a continued improvement in outcomes related to urinary and sexual function. We wish to determine whether these improvements continue to five years and the extent of the difference, at that time, between men with prostate cancer and men without prostate cancer (controls), whom we are also studying. This information will be uniquely useful in helping men make decisions about treatment options when diagnosed with prostate cancer.Read moreRead less